Community Management Services

Social Media Monitoring and Social Response Management

Comprehensive solutions for social media regulatory needs.

Community Management Experience and Capabilities

Webinar icon

Tailored Community Management Services

Customized services to meet your needs.

Tailored Community Management Services

Customized services to meet your needs.

Read Less
Around the world icon

Multilingual Services

35+ languages

Multilingual Services

35+ languages

Read Less
Authority Meetings icon

Highly Qualified Experts

Our team of specialists is proficiently trained in AE and PQC reporting while also providing exceptional levels of service.

Highly Qualified Experts

Our team of specialists is proficiently trained in AE and PQC reporting while also providing exceptional levels of service.

Read Less
Global icon

Global Service Offering

Experience with Community Management Services across the globe. Complying with various regulatory bodies.

Global Service Offering

Experience with Community Management Services across the globe. Complying with various regulatory bodies.

Read Less
Social media icon

Capabilities with Different Platforms

Facebook, Instagram, LinkedIn, X, and more.

Capabilities with Different Platforms

Facebook, Instagram, LinkedIn, X, and more.

Read Less

Social Media Monitoring Services

ProPharma diligently oversees our clients' social media channels, monitoring for any emerging Adverse Events or Product Complaints. Whenever we spot something reportable, we promptly document and report our findings within the required timeframe, ensuring that critical information is not missed.

Social Response Management

ProPharma actively engages with consumer comments and inquiries across various social media platforms acting as the client. We utilize a client-approved standard response document tailored specifically for these interactions. Whether responding publicly to comments beneath posts or privately through direct messages, ProPharma ensures that each interaction is professional, appropriate, and non-promotional. With this service, ProPharma will also remove inappropriate comments from your posts to keep your company’s image professional.

Business professionals smiling at a desk reviewing data
Gradient Image

Contact Us for Expert Community Management Services

We are dedicated to enhancing the health and well-being of consumers through our comprehensive Community Management services. Whether you need reliable Social Media Monitoring Services or full service including Social Response Management, our team of experts is here to help.

News & Insights

Omnichannel Marketing in Pharma: A Strategy Guide for Regulatory Compliance

July 22, 2025

Omnichannel Marketing in Pharma: A Strategy Guide for Regulatory Compliance

Discover how pharma marketers can build effective, compliant omnichannel marketing strategies to drive engagement and meet regulatory requirements.

Mastering Clinical Trial Submissions in Europe: A Guide for Drug Developers

July 21, 2025

Mastering Clinical Trial Submissions in Europe: A Guide for Drug Developers

Discover how to navigate EU clinical trial submissions with confidence. Learn key strategies for CTA success, managing RFIs, and ensuring compliance under EU CTR, MDR, and IVDR.

FMEA Is Not a Crystal Ball: Why You're Missing Critical Risks in Medical Device Lifecycle Management

July 21, 2025

FMEA Is Not a Crystal Ball: Why You're Missing Critical Risks in Medical Device ...

Learn why relying solely on FMEA for medical device risk management falls short and how to adopt a more comprehensive approach to meet ISO 14971 standards.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study From Drafts to First Patient in Record Time - ProPharma

July 8, 2025

From Drafts to First Patient in Record Time

Launching a global clinical study from draft documents, the team achieved US first patient in in 3.5 months and met ambitious global submission timelines. Strong collaboration, proactive planning,...

Whitepapers FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submission

June 23, 2025

FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submiss...

A Strategic Guide to Early FDA Engagement for a Streamlined NDA Pathway For drug developers leveraging the 505(b)(2) NDA pathway, early engagement with FDA is a critical determinant of regulatory...

Case Study Local Expertise, Local Knowledge: MAH in Bosnia and Herzegovina - ProPharma

June 18, 2025

Local Expertise, Local Knowledge: MAH in Bosnia and Herzegovina

Acting as Marketing Authorization Holder in Bosnia and Herzegovina, Clinres—a ProPharma company—helped a global pharma client overcome regulatory delays, misaligned planning, and seasonal launch...

Avoiding Common Pitfalls During FDA Inspections

July 29, 2025

Avoiding Common Pitfalls During FDA Inspections

Starting August 2025, the FDA will conduct unannounced inspections at non-U.S. sites. This webinar explores common inspection pitfalls and how to maintain global inspection readiness with expert...

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

July 22, 2025

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

Gain rare, insider insight into the FDA’s expectations for ANDA submissions in this session led by Marshall Florence, PharmD, a former FDA reviewer who recently joined our team. With firsthand...

MAH Essentials: Ensuring Compliance for European Market Entry

July 10, 2025

MAH Essentials: Ensuring Compliance for European Market Entry

This webinar covers the key responsibilities of Marketing Authorization Applicants/Holders and Qualified Persons in the EEA/UK, including pharmacovigilance requirements, legal entity setup, and...

News & Insights

Omnichannel Marketing in Pharma: A Strategy Guide for Regulatory Compliance

July 22, 2025

Omnichannel Marketing in Pharma: A Strategy Guide for Regulatory Compliance

Discover how pharma marketers can build effective, compliant omnichannel marketing strategies to drive engagement and meet regulatory requirements.

Mastering Clinical Trial Submissions in Europe: A Guide for Drug Developers

July 21, 2025

Mastering Clinical Trial Submissions in Europe: A Guide for Drug Developers

Discover how to navigate EU clinical trial submissions with confidence. Learn key strategies for CTA success, managing RFIs, and ensuring compliance under EU CTR, MDR, and IVDR.

FMEA Is Not a Crystal Ball: Why You're Missing Critical Risks in Medical Device Lifecycle Management

July 21, 2025

FMEA Is Not a Crystal Ball: Why You're Missing Critical Risks in Medical Device ...

Learn why relying solely on FMEA for medical device risk management falls short and how to adopt a more comprehensive approach to meet ISO 14971 standards.

Previous Post Arrow Next Post Arrow
ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study From Drafts to First Patient in Record Time - ProPharma

July 8, 2025

From Drafts to First Patient in Record Time

Launching a global clinical study from draft documents, the team achieved US first patient in in 3.5 months and met ambitious global submission timelines. Strong collaboration, proactive planning,...

Whitepapers FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submission

June 23, 2025

FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submiss...

A Strategic Guide to Early FDA Engagement for a Streamlined NDA Pathway For drug developers leveraging the 505(b)(2) NDA pathway, early engagement with FDA is a critical determinant of regulatory...

Case Study Local Expertise, Local Knowledge: MAH in Bosnia and Herzegovina - ProPharma

June 18, 2025

Local Expertise, Local Knowledge: MAH in Bosnia and Herzegovina

Acting as Marketing Authorization Holder in Bosnia and Herzegovina, Clinres—a ProPharma company—helped a global pharma client overcome regulatory delays, misaligned planning, and seasonal launch...

Previous Resource Arrow Next Resource Arrow
Avoiding Common Pitfalls During FDA Inspections

July 29, 2025

Avoiding Common Pitfalls During FDA Inspections

Starting August 2025, the FDA will conduct unannounced inspections at non-U.S. sites. This webinar explores common inspection pitfalls and how to maintain global inspection readiness with expert...

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

July 22, 2025

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

Gain rare, insider insight into the FDA’s expectations for ANDA submissions in this session led by Marshall Florence, PharmD, a former FDA reviewer who recently joined our team. With firsthand...

MAH Essentials: Ensuring Compliance for European Market Entry

July 10, 2025

MAH Essentials: Ensuring Compliance for European Market Entry

This webinar covers the key responsibilities of Marketing Authorization Applicants/Holders and Qualified Persons in the EEA/UK, including pharmacovigilance requirements, legal entity setup, and...

Previous Webinar Arrow Next Webinar Arrow